These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 12741624

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
    Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S, CNA3002 European Study Team.
    HIV Med; 2001 Jan; 2(1):27-34. PubMed ID: 11737373
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
    Balestre E, Dupon M, Capdepont S, Thiébaut R, Boucher S, Fleury H, Dabis F, Masquelier B, GECSA.
    J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
    [Abstract] [Full Text] [Related]

  • 28. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
    Rozenbaum W, Katlama C, Massip P, Bentata M, Zucman D, Delfraissy JF, Trepo C, David F, Lanier ER, Vavro C, Mamet JP.
    Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
    [Abstract] [Full Text] [Related]

  • 29. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, Pearce G.
    Antivir Ther; 2012 Jun; 17(6):1011-20. PubMed ID: 22910324
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
    Khanlou H, Yeh V, Guyer B, Farthing C.
    AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380
    [Abstract] [Full Text] [Related]

  • 32. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L, EuroSIDA Study Group.
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
    Delaunay C, Brun-Vézinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D.
    J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.